|
N-(3-{[α-D-GalN-(1→4)-α-D-GalN-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide |
|
CHEBI:146255 |
|
N-(3-{[alpha-D-GalN-(1->4)-alpha-D-GalN-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide |
|
A disaccharide derivative in which α-D-galactosaminyl-(1→4)-α-D-galactosamine is linked glycosidically to biotin via a (21-oxo-3,6,9,12,15,18-hexaoxa-22-azapentacosan-1-yl)amino spacer. One of a set of synthesised biotinylated oligo-α-(1→4)-D-galactosamines comprising from two to six monosaccharide units, along with their N-acetylated derivatives (PMID:31913631), aimed at analysing the specificity of the antibody responses to a complex exopolysaccharide galactosaminogalactan found in Aspergillus fumigatus, the most important airborne human fungal pathogen in industrialized countries. |
|
This entity has been manually annotated by the ChEBI Team.
|
|
|
|
Molfile
XML
SDF
|
|
|
|
InChI=1S/C40H74N6O18S/c41-31-35(52)34(51)26(22-47)62-39(31)64-37-27(23-48)63-38(32(42)36(37)53)61-9-3-7-43-30(50)6-10-55-12-14-57-16-18-59-20-21-60-19-17-58-15-13-56-11-8-44-29(49)5-2-1-4-28-33-25(24-65-28)45-40(54)46-33/h25-28,31-39,47-48,51-53H,1-24,41-42H2,(H,43,50)(H,44,49)(H2,45,46,54)/t25-,26+,27+,28-,31+,32+,33-,34-,35+,36+,37-,38-,39+/m0/s1 |
SJABWFIFUAMIDU-ZKLAHFGVSA-N |
[C@H]1([C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)N)O[C@@H]2[C@@H]([C@H]([C@H](O[C@@H]2CO)OCCCNC(CCOCCOCCOCCOCCOCCOCCNC(CCCC[C@H]3[C@]4(NC(N[C@]4(CS3)[H])=O)[H])=O)=O)N)O |
|
Bronsted acid
A molecular entity capable of donating a hydron to an acceptor (Bronsted base).
(via oxoacid )
|
|
View more via ChEBI Ontology
Outgoing
|
N-(3-{[α-D-GalN-(1→4)-α-D-GalN-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide
(CHEBI:146255)
is a
biotins
(CHEBI:51570)
N-(3-{[α-D-GalN-(1→4)-α-D-GalN-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide
(CHEBI:146255)
is a
disaccharide derivative
(CHEBI:63353)
|
|
N-(3-{[2-amino-2-deoxy-α-D-galactopyranosyl-(1→4)-2-amino-2-deoxy-α-D-galactopyranosyl]oxy}propyl)-23-oxo-27-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]-4,7,10,13,16,19-hexaoxa-22-azaheptacosan-1-amide
|
(3aS,4S,6aR)-N-[25-[[2-amino-4-O-(2-amino-2-deoxy-α-D-galactopyranosyl)-2-deoxy-α-D-galactopyranosyl]oxy]-21-oxo-3,6,9,12,15,18-hexaoxa-22-azapentacos-1-yl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide
|
ChEBI
|
3-(21-biotinamino-4,7,10,13,16,19-hexaoxagenicaminoamino)-propyl 2-amino-2-deoxy-α-D-galactopyranosyl-(1→4)-2-amino-2-deoxy-α-D-galactopyranoside
|
ChEBI
|
N-(3-{[2-amino-4-O-(2-amino-2-deoxy-α-D-galactopyranosyl)-2-deoxy-α-D-galactopyranosyl]oxy}propyl)-23-oxo-27-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]-4,7,10,13,16,19-hexaoxa-22-azaheptacosan-1-amide
|
IUPAC
|
N-(3-{[α-D-galactosaminyl-(1→4)-α-D-galactosaminyl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxaheptacosan-1-amide
|
ChEBI
|
31913631
|
PubMed citation
|
Europe PMC
|
|